Centiva Capital LP Has $2.49 Million Stock Position in Novo Nordisk A/S (NYSE:NVO)

Centiva Capital LP lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 138.4% in the 3rd quarter, HoldingsChannel reports. The fund owned 20,898 shares of the company’s stock after purchasing an additional 12,132 shares during the period. Centiva Capital LP’s holdings in Novo Nordisk A/S were worth $2,488,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in NVO. 1620 Investment Advisors Inc. bought a new stake in shares of Novo Nordisk A/S during the second quarter worth about $25,000. Strategic Investment Solutions Inc. IL bought a new stake in shares of Novo Nordisk A/S during the second quarter worth about $25,000. Gilliland Jeter Wealth Management LLC increased its position in shares of Novo Nordisk A/S by 200.0% during the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after acquiring an additional 120 shares in the last quarter. Daiwa Securities Group Inc. bought a new stake in shares of Novo Nordisk A/S during the third quarter worth about $28,000. Finally, Abound Wealth Management increased its position in shares of Novo Nordisk A/S by 257.4% during the second quarter. Abound Wealth Management now owns 218 shares of the company’s stock worth $31,000 after acquiring an additional 157 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Trading Up 1.8 %

Shares of NVO stock opened at $108.70 on Tuesday. Novo Nordisk A/S has a 52-week low of $94.73 and a 52-week high of $148.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The company has a 50-day simple moving average of $112.81 and a two-hundred day simple moving average of $127.92. The company has a market capitalization of $487.77 billion, a price-to-earnings ratio of 35.18, a PEG ratio of 1.38 and a beta of 0.40.

Wall Street Analyst Weigh In

Several research firms have recently commented on NVO. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. Finally, BMO Capital Markets reduced their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $144.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.